Kai Xu

ORCID: 0009-0003-2694-7892
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Acute Myocardial Infarction Research
  • Infective Endocarditis Diagnosis and Management
  • Electrospun Nanofibers in Biomedical Applications
  • Cardiac Valve Diseases and Treatments
  • Aortic Disease and Treatment Approaches
  • Magnetic Properties and Synthesis of Ferrites
  • Retinal and Optic Conditions
  • Retinal Diseases and Treatments
  • Tissue Engineering and Regenerative Medicine
  • Nanoparticle-Based Drug Delivery
  • Characterization and Applications of Magnetic Nanoparticles
  • Cardiac and Coronary Surgery Techniques
  • Polymer Surface Interaction Studies
  • Aortic aneurysm repair treatments
  • Lipoproteins and Cardiovascular Health
  • Venous Thromboembolism Diagnosis and Management
  • Coronary Interventions and Diagnostics
  • Retinal Imaging and Analysis

General Hospital of Shenyang Military Region
2023-2025

Taizhou Second People's Hospital
2020

Yangzhou University
2020

Abstract Anti-inflammation and anti-coagulation are the primary requirements for cardiovascular stents also widely accepted trajectory multi-functional modification. In this work, we proposed an extracellular matrix (ECM)-mimetic coating with amplified functionalization of recombinant humanized collagen type III (rhCOL III), where biomimetics were driven by structure mimicry component/function mimicry. Briefly, structure-mimic was constructed formation a nanofiber (NF) via polymerization...

10.1093/rb/rbad055 article EN cc-by Regenerative Biomaterials 2023-01-01

Objective This study aimed to evaluate the impact of systemic inflammation burden using high-sensitivity C-reactive protein (hsCRP) and long-term prognosis in acute coronary syndrome (ACS) patients undergoing percutaneous intervention (PCI) stratified by bleeding risk status. Methods Consecutive admitted for ACS who received PCI between March 2016 2022 were enrolled analysis. Elevated was defined as hsCRP>2 mg/L, high (HBR) Academic Research Consortium (ARC)-HBR criteria. The primary...

10.1055/a-2531-3268 article EN cc-by Thrombosis and Haemostasis 2025-02-04

Effects of triamcinolone acetonide (TA) combined with aminoguanidine (AG) on vascular endothelial function, growth factor (VEGF) expression and retinal function in diabetic retinopathy (DR) patients were studied. A total 100 DR admitted to the Taizhou Second People's Hospital Affiliated Yangzhou University from January 2016 December 2018 collected randomly divided into observation group (n=50) control (n=50). The was only treated TA (4 mg), while additionally AG (50 mg/kg). therapeutic...

10.3892/etm.2020.8478 article EN Experimental and Therapeutic Medicine 2020-01-30

Objective. To investigate the feasibility of obtaining neo-commissural alignment by withdrawing and readvancing delivery system during transcatheter aortic valve replacement (TAVR) with self-expanding prosthesis. Methods. TAVR was performed in five patients severe stenosis femoral approach. The catheter withdrawn readvanced opposite orientation when Venus-A plus heart (THV) centre marker found to be overlapped or close left at annulus level on fluoroscopic image projection right coronary...

10.1155/2023/1060481 article EN cc-by Journal of Interventional Cardiology 2023-12-11

Abstract Objective: There is limited evidence regarding the choice of P2Y 12 receptor inhibitors as a component dual antiplatelet therapy (DAPT) in patients with left main (LM) disease undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate long-term clinical outcomes ticagrelor- vs. clopidogrel-based DAPT strategy acute syndrome (ACS) LM PCI. Methods: post-hoc analysis from prospective, single-center, real-world PCI registry. A total 1,163 discharged post-ACS who...

10.1097/cd9.0000000000000134 article EN cc-by-nc-nd Cardiology Discovery 2024-10-15
Coming Soon ...